17-N-Allylamino-17-demethoxygeldanamycin: Difference between revisions
Jump to navigation
Jump to search
m Protected "17-N-Allylamino-17-demethoxygeldanamycin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 25: | Line 25: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''17-N-Allylamino-17-demethoxygeldanamycin''' is a substance that is being studied in the treatment of [[cancer]], specific young patients with certain types of [[leukemia]] or solid [[tumors]], especially [[kidney]] [[tumors]]. As of June [[2005]], 17-N-allylamino-17-demethoxygeldanamycin is undergoing Phase 1 and Phase 2 [[clinical trials]]. It belongs to the family of [[medication|drugs]] called [[antineoplastic|antitumor antibiotic]]s. | '''17-N-Allylamino-17-demethoxygeldanamycin''' is a substance that is being studied in the treatment of [[cancer]], specific young patients with certain types of [[leukemia]] or solid [[tumors]], especially [[kidney]] [[tumors]]. As of June [[2005]], 17-N-allylamino-17-demethoxygeldanamycin is undergoing Phase 1 and Phase 2 [[clinical trials]]. It belongs to the family of [[medication|drugs]] called [[antineoplastic|antitumor antibiotic]]s. | ||
| Line 44: | Line 44: | ||
[[Category:Quinones]] | [[Category:Quinones]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 18:50, 8 August 2012
17-N-Allylamino-17-demethoxygeldanamycin is a substance that is being studied in the treatment of cancer, specific young patients with certain types of leukemia or solid tumors, especially kidney tumors. As of June 2005, 17-N-allylamino-17-demethoxygeldanamycin is undergoing Phase 1 and Phase 2 clinical trials. It belongs to the family of drugs called antitumor antibiotics.
References
External links
- Phase 1 trial
- Another Phase 1 trial
- National Cancer Institutie Bulletin on Phase 2 trials against Von Hippel-Lindau disease
- Safety sheet for 17AAG